Equities Analysts Offer Predictions for Revvity Q4 Earnings

Revvity Inc. (NYSE:RVTY - Free Report) - Stock analysts at Zacks Research reduced their Q4 2026 earnings per share estimates for shares of Revvity in a report issued on Tuesday, August 25th. Zacks Research analyst Team now anticipates that the company will post earnings of $1.64 per share for the quarter, down from their previous estimate of $1.67. Zacks Research currently has a "Hold" rating on the stock. The consensus estimate for Revvity's current full-year earnings is $5.36 per share. Zacks Research also issued estimates for Revvity's Q1 2027 earnings at $1.17 EPS, Q4 2027 earnings at $1.77 EPS and FY2027 earnings at $5.86 EPS.

A number of other equities analysts have also recently commented on the stock. Evercore reaffirmed an "outperform" rating on shares of Revvity in a report on Wednesday, August 5th. Weiss Ratings upgraded shares of Revvity from a "sell (d+)" rating to a "hold (c-)" rating in a research note on Thursday, July 30th. Wall Street Zen downgraded shares of Revvity from a "buy" rating to a "hold" rating in a research report on Sunday, August 16th. Wolfe Research initiated coverage on shares of Revvity in a research note on Tuesday, June 2nd. They issued a "peer perform" rating on the stock. Finally, Robert W. Baird set a $117.00 target price on shares of Revvity in a research note on Wednesday, May 6th. Three investment analysts have rated the stock with a Buy rating and twelve have given a Hold rating to the company. According to MarketBeat.com, the company currently has an average rating of "Hold" and an average target price of $108.36.

Revvity Price Performance

RVTY stock opened at $126.31 on Thursday. The company has a market capitalization of $14.09 billion, a P/E ratio of 60.15, a PEG ratio of 2.27 and a beta of 1.07. Revvity has a twelve month low of $81.22 and a twelve month high of $126.90. The business has a 50 day simple moving average of $112.94 and a 200-day simple moving average of $100.82. The company has a current ratio of 1.80, a quick ratio of 1.50 and a debt-to-equity ratio of 0.36.

Revvity (NYSE:RVTY - Get Free Report) last released its quarterly earnings results on Tuesday, August 4th. The company reported $1.41 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.21 by $0.20. The firm had revenue of $729.69 million for the quarter, compared to the consensus estimate of $702.96 million. Revvity had a return on equity of 8.34% and a net margin of 8.16%.The firm's quarterly revenue was down 1.3% compared to the same quarter last year. During the same quarter last year, the business posted $1.18 EPS. Revvity has set its FY 2026 guidance at 5.300-5.400 EPS.

Hedge Funds Weigh In On Revvity

Institutional investors have recently bought and sold shares of the company. AQR Capital Management LLC increased its stake in shares of Revvity by 5.2% during the first quarter. AQR Capital Management LLC now owns 8,449 shares of the company's stock worth $883,000 after acquiring an additional 420 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its position in Revvity by 6.7% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 11,776 shares of the company's stock worth $1,246,000 after purchasing an additional 744 shares during the period. Millennium Management LLC increased its position in Revvity by 102.0% during the 1st quarter. Millennium Management LLC now owns 69,401 shares of the company's stock worth $7,343,000 after purchasing an additional 35,048 shares during the period. Goldman Sachs Group Inc. raised its stake in shares of Revvity by 45.5% during the 1st quarter. Goldman Sachs Group Inc. now owns 607,104 shares of the company's stock worth $64,232,000 after buying an additional 189,871 shares in the last quarter. Finally, Focus Partners Wealth lifted its holdings in shares of Revvity by 13.0% in the 1st quarter. Focus Partners Wealth now owns 7,028 shares of the company's stock valued at $744,000 after buying an additional 811 shares during the period. 86.65% of the stock is owned by institutional investors and hedge funds.

Revvity Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, November 13th. Investors of record on Friday, October 23rd will be given a $0.07 dividend. This represents a $0.28 dividend on an annualized basis and a yield of 0.2%. The ex-dividend date is Friday, October 23rd. Revvity's dividend payout ratio (DPR) is 13.33%.

More Revvity News

Here are the key news stories impacting Revvity this week:

• Positive Sentiment: Zacks raised its FY2026 EPS forecast to $5.38 from $5.25 and its FY2027 forecast to $5.86 from $5.77. Estimates for Q2 2027 and Q1/Q4 2027 were also increased, suggesting analysts see improving earnings momentum beyond the next quarter.
• Positive Sentiment: The revised FY2026 estimate is slightly above the broader consensus of $5.36. Revvity’s latest quarterly results also exceeded expectations, with EPS of $1.41 versus the $1.21 consensus and revenue of $729.7 million versus $703.0 million expected.
• Neutral Sentiment: Zacks maintained a Hold rating, indicating that the higher earnings forecasts have not yet translated into a stronger recommendation. The stock is trading near its 52-week high and carries a relatively elevated price-to-earnings ratio of about 60, which may limit further upside unless earnings growth accelerates. Revvity Faces A New Test After Its Strong Run
• Negative Sentiment: Several near-term and longer-range estimates were trimmed: Q3 2026 EPS fell to $1.27 from $1.30, Q4 2026 to $1.64 from $1.67, Q3 2027 to $1.42 from $1.44, and Q2 2028 to $1.62 from $1.64. These cuts signal some pressure on interim results.

About Revvity

Revvity, Inc is a global provider of technology-enabled solutions for the life sciences, diagnostics and applied markets. The company develops and supplies a range of products and services, including reagents and consumables, laboratory instruments, workflow automation, software analytics and technical support. Its portfolio supports applications in drug discovery, genomics, cell biology research, environmental and food safety testing, industrial quality control and clinical diagnostics.

Tracing its heritage to Perkin-Elmer, founded in 1937, Revvity began trading on the New York Stock Exchange under the ticker symbol RVTY in January 2024 following a corporate rebranding.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source